Crossmark

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

Crossref DOI link: https://doi.org/10.1038/s41422-018-0012-z

Published Online: 2018-02-20

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Du, Xuexiang

Liu, Mingyue

Su, Juanjuan

Zhang, Peng

Tang, Fei

Ye, Peiying

Devenport, Martin

Wang, Xu

Zhang, Yan

Liu, Yang

Zheng, Pan
License Information

Text and Data Mining valid from 2018-02-20
More Information

Article History

Received: 14 September 2017

Revised: 11 December 2017

Accepted: 20 December 2017

First Online: 20 February 2018

Competing interests

: Y.L. and P.Z. are co-founders of, and have equity interests in OncoImmune, Inc.. M.D. is an employee of OncoImmune, Inc. and has an equity interest. The remaining authors declare no competing financial interests.